EHC
Encompass Health CorporationMarquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates | Q2 2021 | 21Q | $65 | $106 | +63% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $86 | $106 | +23% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $86 | $106 | +23% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $86 | $106 | +23% |
| Renaissance Technologies | Q4 2024(8Q snapshot) | 6Q | $102 | $106 | +4% |
| Two Sigma Investments | Q4 2024(8Q snapshot) | 6Q | $100 | $106 | +6% |
| D.E. Shaw | Q4 2024(8Q snapshot) | 6Q | $100 | $106 | +6% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 2× in & out | Q4 2025 | Q2 2026 | → $107 | -6% |
| Glenview Capital 2× in & out | Q4 2025 | Q1 2026 | → $109 | -3% |
| JANA Partners | Q4 2020 | Q2 2023 | → $60 | +8% |
| Maverick Capital 3× in & out | Q3 2021 | Q4 2021 | → $48 | -20% |
| Viking Global Investors | Q2 2020 | Q2 2021 | → $66 | +39% |
| Coatue Management | Q1 2020 | Q2 2020 | → $48 | -21% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Encompass Health Corp. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 18, 2026 — the most recent Form 4 on file — not from today.
- Form 40000785161-26-000158May 18, 2026
- Form 40000785161-26-000153May 12, 2026
- Form 40000785161-26-000148May 11, 2026
- Form 40000785161-26-000146May 11, 2026
- Form 40000785161-26-000144May 11, 2026
- Form 40000785161-26-000142May 11, 2026
- Form 40000785161-26-000140May 11, 2026
- Form 40000785161-26-000138May 11, 2026
- Form 40000785161-26-000136May 11, 2026
- Form 40000785161-26-000134May 11, 2026
- Form 40000785161-26-000132May 11, 2026
- Form 40000785161-26-000125Apr 16, 2026
- Form 40000785161-26-000123Apr 16, 2026
- Form 40000785161-26-000121Apr 16, 2026
- Form 40000785161-26-000119Apr 16, 2026
Fundamentals
XBRL · Encompass Health CorporationAnnual figures sourced directly from Encompass Health Corporation's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Encompass Health Corp — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 1, 2026
- 8-KMaterial eventMay 15, 2026
- 8-KMaterial eventMay 11, 2026
- 10-QQuarterly reportMay 1, 2026
- 8-KMaterial eventApr 30, 2026
- DEF 14AProxy statementApr 7, 2026
- 8-KMaterial eventMar 10, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-K/AMaterial event (amended)Feb 20, 2026
- 8-KMaterial eventFeb 5, 2026
- 8-KMaterial eventFeb 2, 2026
- 8-KMaterial eventDec 1, 2025
- 10-QQuarterly reportOct 31, 2025
- 8-KMaterial eventOct 29, 2025
- 8-KMaterial eventSep 18, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Glenview Capital | Q4 2025 | Q1 2026 | $113 | $109 | -3% |
| Point72 Asset Management | Q4 2025 | Q2 2026 | $113 | $107 | -6% |
| Two Sigma Investments | Q4 2024 | open | $100 | $106 | +6% |
| D.E. Shaw | Q4 2024 | open | $100 | $106 | +6% |
| Renaissance Technologies | Q4 2024 | open | $102 | $106 | +4% |
| Citadel Advisors | Q3 2024 | open | $86 | $106 | +23% |
| AQR Capital Management | Q3 2024 | open | $86 | $106 | +23% |
| Millennium Management | Q3 2024 | open | $86 | $106 | +23% |
| Point72 Asset Management | Q3 2024 | Q1 2025 | $86 | $100 | +16% |
| Glenview Capital | Q4 2021 | Q1 2023 | $48 | $60 | +26% |
| Maverick Capital | Q3 2021 | Q4 2021 | $60 | $48 | -20% |
| Bridgewater Associates | Q2 2021 | open | $65 | $102 | +57% |
| JANA Partners | Q4 2020 | Q2 2023 | $55 | $60 | +8% |
| Maverick Capital | Q2 2020 | Q2 2021 | $48 | $66 | +35% |
| Viking Global Investors | Q2 2020 | Q2 2021 | $47 | $66 | +39% |
| Coatue Management | Q1 2020 | Q2 2020 | $61 | $48 | -21% |
| Maverick Capital | Q4 2019 | Q1 2020 | $51 | $61 | +20% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.